Closed
The Marked Chart Wire · Health
Eli Lilly
Eli Lilly stock climbed 1.89 percent in after-hours trading following favorable Phase 3 data for its diabetes drug retatrutide, ahead of upcoming quarterly earnings.
Prices from Before the open · based on Wed close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Retatrutide
Eli Lilly reported that its investigational drug retatrutide outperformed Ozempic in a Phase 3 trial for type 2 diabetes. The new drug achieved greater weight loss and A1C reduction over 80 weeks, marking its sixth positive Phase 3 result.
GLP-1
Large firms are reducing coverage for GLP-1 medications, with 53 percent offering plans in 2026. Marsh forecasts an 8.2 percent jump in per-employee premiums for 2027, pushing workers toward out-of-pocket payments.
Weight-Loss Drugs
A court rejected Novo Nordisk's legal effort to stop Eli Lilly from advertising its weight-loss medications, clearing the way for the company to continue its marketing campaign.
Enhertu
AstraZeneca paid a $75 million milestone to Daiichi Sankyo following European Union approval of the therapy for early-stage HER2-positive breast cancer. Trial results showed a 53 percent reduction in recurrence or death risk compared to T-DM1.
PACIFIC-9
AstraZeneca updated the timeline for its PACIFIC-9 phase 3 trial in non-small cell lung cancer, moving the data readout from the second half of 2026 to the first half of 2027. Enrollment for the study is complete.
Bristol Myers Squibb
Bristol Myers Squibb announced that its cancer treatment doubled the time patients lived without disease progression. The drug also showed promising results in other solid tumors.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.